Chinese Herbal Medicine for Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials

• Published in: Frontiers in pharmacology Vol. 12; p. 573500
• Main Authors: Wang, Qing, Ye, Hui, Wang, Qiu-Qin, Li, Wei-Tong, Yu, Bei-Bei, Bai, Ya-Mei, Xu, Gui-Hua
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.05.2021
• Subjects: chemotherapy-induced leukopenia; Chinese herbal medicine; meta-analysis; Pharmacology; systematic review; traditional Chinese medicine; meta-analysis; Chinese herbal medicine; traditional Chinese medicine; systematic review; chemotherapy-induced leukopenia
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2021.573500

We conducted a systematic review of high-quality randomized controlled trials (RCTs) to assess the efficacy and safety of Chinese herbal medicine (CHM) for the treatment of chemotherapy-induced leukopenia (CIL). Eight electronic databases were searched from the date of inception to November 4, 2020 for high-quality RCTs that met the requirements of at least four key domains of the Cochrane risk of bias (RoB) tool. RevMan 5.3 was applied for the meta-analysis. Fourteen RCTs involving 1,053 patients were included. The pooled results showed that CHM + chemotherapy exerted greater beneficial effects on white blood cell (WBC), neutrophil (NEU), hemoglobin (Hb), and platelet (PLT) counts in addition to the Karnofsky performance scale (KPS) score, but showed no significant difference on granulocyte colony-stimulating factor (G-CSF) dosage compared with chemotherapy alone. Placebo (PBO) + chemotherapy and CHM + chemotherapy groups showed no significant differences in terms of reduction of the incidence of neutropenia. CHM + chemotherapy was superior to Western medicine (WM) + chemotherapy in improving the WBC count, KPS, infection amount, G-CSF use rate, and incidence of leukopenia. In addition, no severe adverse events were observed in the 14 RCTs. CHM in combination with chemotherapy could effectively improve the clinical symptoms of CIL when compared with chemotherapy alone or Western medicine + chemotherapy, except when comparing with PBO + chemotherapy. While CHMs were generally safe for clinical use and exerted no severe side effects in the 14 RCTs, high-quality RCTs with larger sample sizes are essential to reduce study heterogeneity.